
    
      1. To evaluate the response rate of lapatinib and capecitabine combination in patients with
           metastatic colon or rectal cancer.

        2. To evaluate the toxicity and tolerability of lapatinib and capecitabine in this
           population.

        3. To determine overall survival and disease free survival of lapatinib and capecitabine.
    
  